{"filing":{"accession_number":"0001213900-26-074576","cik":"0000072444","ticker":"VXRT","company_name":"Vaxart, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"ea0296709-8k_vaxart.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/72444/000121390026074576/ea0296709-8k_vaxart.htm"},"events":[{"id":15664,"run_id":13965,"accession_number":"0001213900-26-074576","anchor_item_number":"1.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.8,"summary":"Vaxart entered into a Cooperation Agreement with a stockholder group that resolves a proxy contest through comprehensive governance enhancements, including the appointment of a mutually agreed independent director, formation of new board committees (Stockholder Engagement and Clinical and Regulatory Affairs), adoption of director stock ownership and resignation policies, and quarterly management engagement.","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13528,"accession_number":"0001213900-26-074576","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure centers on a Cooperation Agreement resolving a proxy contest through governance enhancements: withdrawal of director nominations by the Stockholder Group, appointment of a mutually agreed independent director, formation of new board committees (Stockholder Engagement and Clinical and Regulatory Affairs), adoption of director stock ownership and resignation policies, and quarterly management engagement. While the agreement involves board composition changes, the principal event is the settlement of a proxy dispute through governance reforms rather than a single executive appointment or departure, making governance_other the most precise classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:40.288910+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13529,"accession_number":"0001213900-26-074576","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Vaxart announced a cooperation agreement with a stockholder group that resolves a proxy contest through governance enhancements: appointment of a mutually agreed independent director, formation of new board committees (Stockholder Engagement and Clinical and Regulatory Affairs), committee refreshment, and adoption of director stock ownership and resignation policies. While the agreement involves director appointment, the central disclosure is the resolution of a proxy fight through comprehensive governance reforms rather than a single executive appointment, making this a governance restructuring event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:40.288910+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13528,"accession_number":"0001213900-26-074576","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"This disclosure centers on a Cooperation Agreement resolving a proxy contest through governance enhancements: withdrawal of director nominations by the Stockholder Group, appointment of a mutually agreed independent director, formation of new board committees (Stockholder Engagement and Clinical and Regulatory Affairs), adoption of director stock ownership and resignation policies, and quarterly management engagement. While the agreement involves board composition changes, the principal event is the settlement of a proxy dispute through governance reforms rather than a single executive appointment or departure, making governance_other the most precise classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:40.288910+00:00","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-07-02"},{"id":13529,"accession_number":"0001213900-26-074576","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Vaxart announced a cooperation agreement with a stockholder group that resolves a proxy contest through governance enhancements: appointment of a mutually agreed independent director, formation of new board committees (Stockholder Engagement and Clinical and Regulatory Affairs), committee refreshment, and adoption of director stock ownership and resignation policies. While the agreement involves director appointment, the central disclosure is the resolution of a proxy fight through comprehensive governance reforms rather than a single executive appointment, making this a governance restructuring event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:21:40.288910+00:00","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-07-02"}]}